| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e1cf2b6a05b2813470de8b31197ca7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b2a0658b70350fa81417e3b44adf57 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bf1d992110c9e0209a1e9394df803ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20395f9e9b212931292dc6ec809df6c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88c43b97d604d41d8fcfcc659dac46fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23dbf01f8022acdd2aff3213858bac2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbbe9f223fe36361dd4169bb9a05c3ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f359bf7d6be13e2d6bbf9a70b8df18d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bf7956de8ed55f44f75ebd837b710d6 |
| publicationDate |
2022-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115003332-A |
| titleOfInvention |
Use of anti-PD-1 antibody in combination with fruquintinib in the preparation of a drug for the treatment of cancer |
| abstract |
Use of an anti-PD-1 antibody or an antigen-binding fragment thereof in combination with fruquintinib or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer. The combination of anti-PD-1 antibody and fruquintinib has a certain synergistic effect. Compared with the corresponding single drug, the effect of inhibiting tumor growth is obvious. During the administration period, the experimental animals tolerated it well, and no adverse reactions were observed. |
| priorityDate |
2020-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |